Giuseppe Leone: This Review by Offidani’s Group Compares Clinical Trials and Outlines Prospects
LABORATORY Professionals International reposted Giuseppe Leone’s post on LinkedIn:
“At major international conferences in 2024, important data emerged on new approaches capable of improving outcomes even in high-risk or very advanced disease. Upfront quadruplet combinations, including anti-CD38 monoclonal antibodies, have proven to be the best therapy in terms of depth of response and long-term efficacy in both transplant-eligible and ineligible patients. Despite the introduction of these therapies, high-risk multiple myeloma (MM) remains challenging to treat. This review by Offidani’s group compares clinical trials and outlines prospects.”
Title: Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES
Authors: Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
Read more here.
Stay updated with Hemostasis Today.
-
Nov 6, 2025, 08:24Jacqui McCallum Reflects on Meeting with The Royal Melbourne Hospital Stroke and Neurology Ward Team
-
Nov 6, 2025, 08:17Maxime Dely: The True Heroes of Blood Donation Are Them!
-
Nov 6, 2025, 07:11Francesco Giurazza on Radial Access for Liver Transarterial Chemoembolization
-
Nov 6, 2025, 07:04Andrea Van Beek: Proud to be a Certified Anticoagulation Care Provider (CACP)!
-
Nov 6, 2025, 06:57Jian-Ke Tie’s Team on Comorbidity of VitK-dependent Clotting Factors Deficiency and Chondrodysplasia Punctata
-
Nov 6, 2025, 04:17Aakanksha A To Present Insights from ASH Education Social Media Initiative at 67th ASH Meeting
-
Nov 6, 2025, 04:03Yaping Zhang on Two-Way GPIb-IX Signaling in Platelet Activation and VWF Binding
-
Nov 6, 2025, 03:38Thierry Burnouf on Platelet-Derived Extracellular Vesicles and Their Role in Neurogenesis
-
Nov 6, 2025, 03:29Shubham Misra to Present 3 Abstracts at International Stroke Conference 2026